These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32692628)

  • 41. Biosimilars And Follow-On Products In The United States: Adoption, Prices, And Users.
    Stern AD; Chen JL; Ouellet M; Trusheim MR; El-Kilani Z; Jessup A; Berndt ER
    Health Aff (Millwood); 2021 Jun; 40(6):989-999. PubMed ID: 34097520
    [TBL] [Abstract][Full Text] [Related]  

  • 42. US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.
    Kim MS; Prasad V
    Cancer; 2020 Oct; 126(19):4270-4272. PubMed ID: 32644193
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Role of Biosimilars.
    Zelenetz AD; Becker PS
    J Natl Compr Canc Netw; 2016 May; 14(5 Suppl):626-9. PubMed ID: 27226500
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
    Shanafelt TD; Borah BJ; Finnes HD; Chaffee KG; Ding W; Leis JF; Chanan-Khan AA; Parikh SA; Slager SL; Kay NE; Call TG
    J Oncol Pract; 2015 May; 11(3):252-8. PubMed ID: 25804983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current market and regulatory landscape of biosimilars.
    Bhatt V
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S451-S456. PubMed ID: 30452213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Talking to patients about biosimilars.
    Janjigian YY; Bissig M; Curigliano G; Coppola J; Latymer M
    Future Oncol; 2018 Oct; 14(23):2403-2414. PubMed ID: 29856243
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initial steps in the regulation of generic biological drugs: a comparison of U.S. and Canadian regimes.
    Szeto KJ; Wolanski M
    Food Drug Law J; 2012; 67(2):131-41, i. PubMed ID: 24620416
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The complexities of biosimilars and the regulatory approval process.
    Lucio S
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S231-S236. PubMed ID: 29957908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biosimilars: what the oncologist should know.
    Thill M; Thatcher N; Hanes V; Lyman GH
    Future Oncol; 2019 Apr; 15(10):1147-1165. PubMed ID: 30793950
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biosimilars in inflammatory bowel disease: A review of post-marketing experience.
    Deiana S; Gabbani T; Annese V
    World J Gastroenterol; 2017 Jan; 23(2):197-203. PubMed ID: 28127193
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
    Glode AE; Jarkowski A
    Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BIOSIMILARS AND NEW INSULIN VERSIONS.
    Peters AL; Pollom RD; Zielonka JS; Carey MA; Edelman SV
    Endocr Pract; 2015 Dec; 21(12):1387-94. PubMed ID: 26340139
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The emergence of follow-on disease-modifying therapies for multiple sclerosis.
    Moss BP; Cohen JA
    Mult Scler; 2019 Oct; 25(12):1560-1565. PubMed ID: 31074707
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway.
    Rasmussen JT; Ipema HJ
    Ann Pharmacother; 2019 Feb; 53(2):204-210. PubMed ID: 30122087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The consumer welfare implications of governmental policies and firm strategy in markets for medicines.
    Chatterjee C; Kubo K; Pingali V
    J Health Econ; 2015 Dec; 44():255-73. PubMed ID: 26581076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
    Kubuschok B; Trepel M
    Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment and management of chronic lymphocytic leukemia in the elderly: what the pharmacist clinician should know.
    Johnson TM
    Consult Pharm; 2012 Apr; 27(4):274-85. PubMed ID: 22498987
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India.
    Jain D; Darrow JJ
    Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.